Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose for exercise capacity in iron-deficient chronic heart failure
2011-000603-40Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose in chronic heart failure (CHF) and iron deficiency anemia (IDA) (2 arms), sponsored by CSL Vifor. Primary endpoint: Change in peak VO2 from baseline to Week 24. Started May 2011; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
chronic heart failure (CHF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2011-000603-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000603-40.